MindMed’s stock soars 51.5% after FDA grants breakthrough designation to LSD therapy for a form of anxiety


The FDA’s move will speed up development of MindMed’s LSD-based drug as a treatment for generalized anxiety disorder.


Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button